(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.67%) $79.53
(1.14%) $1.954
(0.80%) $2 329.60
(0.36%) $26.85
(1.31%) $967.40
(0.00%) $0.933
(-0.04%) $11.02
(-0.09%) $0.798
(-0.26%) $93.02
@ $3.89
发出时间: 14 Feb 2024 @ 04:43
回报率: -0.90%
上一信号: Feb 13 - 22:30
上一信号:
回报率: -4.07 %
Live Chart Being Loaded With Signals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections...
Stats | |
---|---|
今日成交量 | 405 230 |
平均成交量 | 359 865 |
市值 | 324.03M |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $-0.610 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.36 |
ATR14 | $0.00500 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-31 | Corcoran Andrea | Buy | 44 367 | Common Stock |
2024-02-01 | Corcoran Andrea | Sell | 15 843 | Common Stock |
2024-01-31 | Corcoran Andrea | Buy | 200 000 | Stock Option (Right to Buy) |
2024-01-31 | Corcoran Andrea | Sell | 44 367 | Restricted Stock Units |
2024-01-31 | Sommadossi Jean-pierre | Buy | 448 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
72.65 |
Last 99 transactions |
Buy: 22 764 762 | Sell: 12 804 280 |
音量 相关性
Atea Pharmaceuticals, 相关性 - 货币/商品
Atea Pharmaceuticals, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-416 000 (0.00 %) |
EPS: | $-1.630 |
FY | 2023 |
营收: | $0 |
毛利润: | $-416 000 (0.00 %) |
EPS: | $-1.630 |
FY | 2022 |
营收: | $0 |
毛利润: | $-260 000 (0.00 %) |
EPS: | $-1.390 |
FY | 2021 |
营收: | $351.37M |
毛利润: | $0.00 (0.00 %) |
EPS: | $5.61 |
Financial Reports:
No articles found.
Atea Pharmaceuticals,
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。